^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted CAR-T immunotherapy

    Related drugs:
    1d
    KarMMa-9: A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P3, N=79, Active, not recruiting, Celgene | N=618 --> 79 | Trial completion date: Aug 2025 --> Nov 2029
    Enrollment change • Trial completion date
    |
    lenalidomide • cyclophosphamide • fludarabine IV • Abecma (idecabtagene vicleucel)
    2d
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca | N=64 --> 40
    Enrollment change
    |
    AZD0120
    3d
    BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    lenalidomide • cyclophosphamide • fludarabine IV
    3d
    KarMMa-2: An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=312, Completed, Celgene | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    lenalidomide • Abecma (idecabtagene vicleucel) • Talvey (talquetamab-tgvs)
    4d
    Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Beijing GoBroad Hospital | Not yet recruiting --> Recruiting | Trial completion date: Jul 2026 --> Dec 2027 | Initiation date: Sep 2025 --> Mar 2026
    Enrollment open • Trial completion date • Trial initiation date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV
    4d
    Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain. (PubMed, J Immunother Cancer)
    Incorporating a CD28-TMD into the ARI0002h CAR enhances tumor control even in relapse models with downregulation of the target antigen, offering improved long-term disease management. This modification increases potency against MM tumor cell lines with both normal and reduced BCMA expression, demonstrating superior metabolic endurance and in vivo activity.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    cesnicabtagene autoleucel (ARI0002h)
    5d
    A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=18, Recruiting, Hangzhou Qihan Biotech Co., Ltd.
    New P1 trial
    7d
    Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study (clinicaltrials.gov)
    P1, N=12, Recruiting, Hebei Senlang Biotechnology Inc., Ltd.
    New P1 trial
    |
    senl_BCMA
    12d
    A Machine Learning-Guided Approach for Identifying Potential HCAR1 Antagonists in Lactate-Driven Cancers. (PubMed, ACS Omega)
    An SVM model was trained on 144 ligands (66 agonists, 78 antagonists), listed in the IUPHAR/BPS Guide to Pharmacology, from 12 structurally related Class A GPCRs (HCAR1, HCAR2, HCAR3, OXER1, GPR35, SUCNR1, P2Y2, MCHR1, OPRD1, AGTR1, ADORA2A, and ADRA1A)...Based on ΔAffinity, off-target scores, and prediction confidence, Ketanserin, Cryptopyranmoscatone A1 diacetate, and Cefuroxime emerged as reference ligands with promising antagonistic potential, two of which are FDA-approved drugs...Overall, this work presents a proof-of-concept framework that integrates conformational docking, machine learning, and substructure interpretation to elucidate the chemical and structural determinants of HCAR1 antagonism. The findings provide fragment-level insights that may guide future bioisosteric and fragment-based design of selective antagonists for lactate-driven tumors.
    Journal
    |
    ADORA2A (Adenosine A2a Receptor) • MAGEE1 (MAGE family member E1) • SUCNR1 (Succinate Receptor 1)
    15d
    Musculoskeletal Adverse Events Following BCMA CAR-T Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates. (PubMed, Transplant Cell Ther)
    MSK AEs represent a common, under-recognized toxicity affecting nearly one-third of BCMA CAR-T recipients, often causing severe and prolonged disability. The identification of predictive baseline PMN-MDSC reduction and persistent inflammatory cytokine elevation provides insights into pathophysiology and suggests potential for risk stratification and targeted therapeutic intervention. These findings warrant prospective validation and development of standardized assessment and management protocols.
    Journal • Adverse events • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CCL4 (Chemokine (C-C motif) ligand 4)
    |
    Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel)
    16d
    Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, Hebei Senlang Biotechnology Inc., Ltd.
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    17d
    A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P1 trial
    |
    SELP (Selectin P)
    |
    cyclophosphamide